Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Entero Healthcare Solutions's Debt-to-EBITDA or its related term are showing as below:
NSE:ENTERO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.86 Med: 4.77 Max: 13.62
Current: 2.11
During the past 6 years, the highest Debt-to-EBITDA Ratio of Entero Healthcare Solutions was 13.62. The lowest was 1.86. And the median was 4.77.
NSE:ENTERO's Debt-to-EBITDA is ranked better than 54.95% of 91
companies
in the Medical Distribution industry
Industry Median: 2.31
vs NSE:ENTERO: 2.11
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Entero Healthcare Solutions Debt-to-EBITDA Related Terms
Entero Healthcare Solutions Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ENTERO vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Entero Healthcare Solutions's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entero Healthcare Solutions Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Entero Healthcare Solutions's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Entero Healthcare Solutions's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Entero Healthcare Solutions (NSE:ENTERO) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Entero Healthcare Solutions. Over the past decade, Entero Healthcare Solutions' Debt-to-EBITDA has ranged from 1.86 to 13.62. According to the industry distribution chart, Entero Healthcare Solutions ranks #41 out of 91 companies in the Medical Distribution industry, placing it in the top 45.1%.
Is Entero Healthcare Solutions' Debt-to-EBITDA too high?
Entero Healthcare Solutions' current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 1.86 to a high of 13.62. Based on the distribution chart, Entero Healthcare Solutions ranks #41 out of 91 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Entero Healthcare Solutions has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Entero Healthcare Solutions' Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Entero Healthcare Solutions ranks #41 out of 91 companies for Debt-to-EBITDA. This puts Entero Healthcare Solutions in the upper half of its industry. The industry median Debt-to-EBITDA is 2.31. Historically, Entero Healthcare Solutions' own Debt-to-EBITDA has ranged from 1.86 to 13.62 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.31, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Entero Healthcare Solutions. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entero Healthcare Solutions's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entero Healthcare Solutions stock overvalued right now?
Based on GuruFocus' analysis, Entero Healthcare Solutions (NSE:ENTERO) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,749.26, compared to a current price of ₹1,808.60 — trading 3.4% above its estimated fair value. The current Debt-to-EBITDA is 0.00. Entero Healthcare Solutions' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Entero Healthcare Solutions (NSE:ENTERO), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entero Healthcare Solutions (NSE:ENTERO) Overvalued in 2026?
Based on GuruFocus' analysis, Entero Healthcare Solutions stock appears to be overvalued.
The current stock price of ₹1,808.60 is trading 3.4% above its estimated GF Value™ of ₹1,749.26.
GuruFocus considers Entero Healthcare Solutions to be Fairly Valued.
Key valuation signals for NSE:ENTERO:
Debt-to-EBITDA: 0.00
GF Value™: ₹1,749.26 vs. price of ₹1,808.60 (3.4% above fair value)
No single metric tells the full story. See the NSE:ENTERO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entero Healthcare Solutions Ltd is a healthcare products distributor in India. It is involved in the business of distribution and marketing of pharmaceutical and surgical products and allied services. Geographically, the company derives a majority of its revenue from the domestic market.
64GF Score
Get the complete analysis for NSE:ENTERO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ENTERO has been successfully added to your 
